How does human papillomavirus contribute to head and neck cancer development?

Journal of the National Cancer Institute

Volumn 96, Issue 13, 2004, Pages 978-979

  Mao, Li ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7; VIRUS DNA; VIRUS PROTEIN;

CHROMOSOME DELETION; DNA INTEGRATION; EDITORIAL; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; WART VIRUS; GENETICS; HEAD AND NECK TUMOR; ISOLATION AND PURIFICATION; NOTE; PAPILLOMA VIRUS; PHENOTYPE; VIROLOGY; VIRUS INFECTION;

CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; HEAD AND NECK NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHENOTYPE;

EID: 4444374017     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh209     Document Type: Editorial

References (24)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2000; 55:244-65.
2. Ault KA. Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine. Obstet Gynecol Clin North Am 2003;30:809-17.
3. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46-54.
4. Gillison M, Koch WM, Shah KV. Human papillomavirus and head and neck squamous cell carcinoma: are some head and neck cancers sexually transmitted disease? Curr Opin Oncol 1999;11:191-9.
5. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
6. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-31.
7. Braakhuis BJM, Snijders PJF, Keune WJH, Meijer CJLM, Ruijter-Scheppers HJ, Leemans CR, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004;96:998-1006.
8. Dai M, Clifford GM, le Calvez F, Castellsague X, Snijders PJ, Pawlita M, et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 2004;64:468-71.
9. von Knebel Doeberitz M, Rittmuller C, zur Hausen H, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 1992;51:831-4.
10. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Hettelman W, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2: 682-5.
11. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
12. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999;97:53-61.
13. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
14. Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, et al. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 1997;14:1799-803.
15. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
16. Hafkamp HC, Speel EJ, Haesevoets A, Bot FJ, Dinjens WN, Ramaekers FC, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003;107:394-400.
17. Becker NA, Thorland EC, Denison SR, Phillips LA, Smith DI. Evidence that instability within the FRA3B region extends four megabases. Oncogene 2002;21:8713-22.
18. Mao L, Fan YH, Lotan R, Hong WK. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 1996;56:5128-31.
19. Segawa T, Sasagawa T, Yamazaki H, Sakaike J, Ishikawa H, Inoue M. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma. Cancer 1999;85:2001-10.
20. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
21. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002;8:3187-92.
22. Li W, Thompson CH, O'Brien CJ, McNeil EB, Scolyer RA, Cossart YE, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003;106:553-8.
23. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92: 805-13.
24. Koutsky LA, Ault K, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.